186 related articles for article (PubMed ID: 31465304)
1. Use of Topical Intraocular Pressure-lowering Medications in the US Population: Results From the NHANES Study 1999 to 2014.
Lowry EA; Chansangpetch S; Lin SC
J Glaucoma; 2019 Sep; 28(9):772-776. PubMed ID: 31465304
[TBL] [Abstract][Full Text] [Related]
2. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Patients Receiving Treatment Who Deny A Diagnosis Glaucoma or Elevated Intraocular Pressure in the United States.
Lowry EA; Mansberger SL
J Glaucoma; 2018 Nov; 27(11):1029-1031. PubMed ID: 30059410
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study.
Sheer R; Bunniran S; Uribe C; Fiscella RG; Patel VD; Chandwani HS
J Manag Care Spec Pharm; 2016 Jul; 22(7):808-817a. PubMed ID: 27348282
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy for glaucoma: what to add after a prostaglandin analogs?
Tanna AP; Lin AB
Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765
[TBL] [Abstract][Full Text] [Related]
6. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.
Rahimy E; Ying GS; Pan W; Hsu J
Retina; 2019 Apr; 39(4):636-647. PubMed ID: 29517580
[TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
Juncal VR; Abdo Jorge F; Paranhos A; Santos Prata T
Can J Ophthalmol; 2015 Aug; 50(4):297-301. PubMed ID: 26257224
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of intraocular pressure-lowering medication determined by washout.
Jampel HD; Chon BH; Stamper R; Packer M; Han Y; Nguyen QH; Ianchulev T
JAMA Ophthalmol; 2014 Apr; 132(4):390-5. PubMed ID: 24481483
[TBL] [Abstract][Full Text] [Related]
9. Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.
Iskedjian M; Walker JH; Desjardins O; Robin AL; Covert DW; Bergamini MV; Einarson TR
Curr Med Res Opin; 2009 Aug; 25(8):1879-88. PubMed ID: 19530975
[TBL] [Abstract][Full Text] [Related]
10. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
Brandt JD; Beiser JA; Gordon MO; Kass MA;
Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
[TBL] [Abstract][Full Text] [Related]
11. The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007.
Lin JC
J Glaucoma; 2015; 24(5):364-71. PubMed ID: 26039384
[TBL] [Abstract][Full Text] [Related]
12. Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017.
Perera N; Pinnuck BC; Jamieson MPH; Ling D; Williams M; Chen O
J Glaucoma; 2020 Mar; 29(3):175-183. PubMed ID: 31790066
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study.
Choi EY; Johnson NA; Stinnett S; Rosdahl J; Moya F; Herndon LW
J Glaucoma; 2024 Jun; 33(6):431-436. PubMed ID: 38506759
[TBL] [Abstract][Full Text] [Related]
14. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
15. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
King AJ; Rotchford AP
JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal effect of topical antiglaucoma medications on central corneal thickness.
Viswanathan D; Goldberg I; Graham SL
Clin Exp Ophthalmol; 2013; 41(4):348-54. PubMed ID: 22958109
[TBL] [Abstract][Full Text] [Related]
17. Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs.
Lee SS; Robinson MR; Weinreb RN
J Glaucoma; 2019 Sep; 28(9):846-857. PubMed ID: 31261285
[TBL] [Abstract][Full Text] [Related]
18. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides.
Martínez A; Sánchez M
Curr Med Res Opin; 2007 Mar; 23(3):595-9. PubMed ID: 17355740
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
